Navigation Links
Resverlogix desincorpora RVX Therapeutics Inc. para sus accionistas
Date:4/8/2013

CALGARY, Alberta, April 8, 2013 /PRNewswire/ --

La transacción se diseña para mejorar el valor de los accionistas por medio del desbloqueo del valor de la plataforma epigenética

TSX Exchange Symbol: RVX

Resverlogix Corp. (TSX:RVX) ("Resverlogix") anunció hoy que su consejo de dirección ha aprobado una proposición de desincorporación de su filial, RVX Therapeutics Inc. ("RVX Therapeutics"), que se centrará en el desarrollo e investigación de fármacos innovadores por medio de la mejora de su plataforma epigenética. RVX Therapeutics excluirá la apolipoproteína A-1 ("Apo A-1") y tecnologías RVX-208, en lugar de centrarse en múltiples indicaciones terapéuticas, incluyendo las enfermedades autoinmunes y el cáncer.

La desvinculación se implementará a través de un Plan de Acuerdo ("al acuerdo") implementado por un tribunal tras la Business Corporations Act (Alberta). La implementación del acuerdo estará pendiente, entre otras cosas, a la aprobación final del consejo del acuerdo y de los votos de los accionistas.

Razones

La desincorporación de RVX Therapeutics refleja la creencia del consejo de dirección y del consejo de administración de que los mejores intereses para los accionistas están en la creación de un valor futuro para su plataforma epigenética y proporcionar un mecanismo de retención de los royalties futuros posibles sobre las ventas de RVX-208, dependiendo de la estructura del acuerdo finalmente negociada.

Basándose en la creencia de la que el programa RVX-208 contabiliza actualmente el valor de mercado completo de Resverlogix y de que el valor de la plataforma epigenética no se ha conseguido, la desincorporación de RVX Therapeutics facilitará una estructura empresarial que es muy posible refle
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Galectin Therapeutics: Turning Atlanta into Americas Next Silicon Valley
2. Galectin Therapeutics Reports Full Year and Fourth Quarter 2012 Financial Results
3. Aratana Therapeutics Adds To Drug Development Team
4. Biovista und DART Therapeutics nehmen Zusammenarbeit auf, um auf Duchenne-Muskeldystrophie abzielende Medikamente neu zu positionieren
5. Novira Therapeutics Completes $25 Million Series A Financing
6. Peptide Therapeutics Market is Expected to Reach USD 25.4 Billion Globally in 2018: Transparency Market Research
7. Pain Therapeutics - Drugs, Markets and Companies - 2013 Report
8. Genedata Expressionist for Mass Spectrometry Showcased at 2013 Biotherapeutics Analytical Summit
9. Array Biopharma and Global Blood Therapeutics Announce Drug Discovery Collaboration Focused on Hematology
10. Comprehensive Global Testing Solutions for Novel Hepatitis C Therapeutics, New Webinar Hosted by Xtalks
11. United Therapeutics Corporation To Announce Fourth Quarter And Annual 2012 Financial Results Before Market Open On Tuesday, February 26, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 17, 2014 The Pistoia Alliance, ... lowering the barriers to innovation in life sciences ... of Carmen Nitsche as Executive Director Business Development ... its global reach. , Carmen joins the Pistoia ... Corporate Development. At Accelrys, she managed various life ...
(Date:9/16/2014)... 2014 This report analyzes the worldwide markets for ... Hardware, and Biocontent. The report provides separate comprehensive analytics for ... , Europe , Asia-Pacific ... of World. Annual estimates and forecasts are provided for the ... provided for these markets. Market data and analytics are derived ...
(Date:9/16/2014)... September 16, 2014 --The emerging field of molecular ... the next level, enabling the construction of tiny ... devices, individual molecules would take on the roles ... , A team of researchers from five Japanese ... for use in small-scale electronics: a molecule called ...
(Date:9/16/2014)... 16, 2014 BlueInGreen® , ... efficient method for delivering dissolved gases into liquids, ... as a manufacturer’s representative firm to its ... products for municipal water and wastewater applications in ... H2Flow was founded in 1992 and serves Quebec ...
Breaking Biology Technology:Pistoia Alliance Expands Business Development with Appointment of Carmen Nitsche 2Global Bioinformatics Industry 2Global Bioinformatics Industry 3Global Bioinformatics Industry 4Global Bioinformatics Industry 5Global Bioinformatics Industry 6Global Bioinformatics Industry 7Global Bioinformatics Industry 8Global Bioinformatics Industry 9Global Bioinformatics Industry 10Global Bioinformatics Industry 11Global Bioinformatics Industry 12Global Bioinformatics Industry 13Global Bioinformatics Industry 14Global Bioinformatics Industry 15Global Bioinformatics Industry 16Global Bioinformatics Industry 17Global Bioinformatics Industry 18Global Bioinformatics Industry 19Global Bioinformatics Industry 20Global Bioinformatics Industry 21Global Bioinformatics Industry 22Global Bioinformatics Industry 23The future face of molecular electronics 2BlueInGreen® Expands into Canada – Signs Representative Agreement with H2Flow Equipment Inc. 2
... 2008 - Vol. 299. No. 8: ,Venous Thromboembolism and ... Administration for the Treatment of Cancer-Associated ... believes that,the conclusions of a study published in the ... Medical Association (JAMA) by Bennett, et al, do,not provide ...
... 26 CV Therapeutics,Inc. (Nasdaq: CVTX ) today reported ... 31, 2007., For the quarter ended December 31, 2007, ... per share. This compares to a net loss of,$68.1 million, ... and $34.2,million, or $0.58 per share, for the prior quarter ...
... REINACH, Switzerland, February 26 Arpida Ltd.,(SWX: ARPN) today ... (NDA) for intravenous iclaprim in its first indication,complicated Skin ... next few weeks., Arpida has agreed with the ... in a rolling process. Using a ,rolling NDA, allows ...
Cached Biology Technology:Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents 2Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents 3Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents 4Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents 5Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents 6CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 2CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 3CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 4CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 5CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 6CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 7CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 8Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim 2Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim 3
(Date:9/16/2014)... rock hit the Yukatan peninsula near the site of the ... of TNT. It left a crater more than 150 km ... are widely accepted to have wiped out the dinosaurs and ... happened to the plants on which the dinosaurs fed? , ... Arizona reveals that the meteorite impact that spelled doom for ...
(Date:9/16/2014)... A complex web of interaction between viruses, bacteria, ... by a growing international collaboration between Matthew Sullivan, ... of Ecology and Evolutionary Biology and Steven Hallam ... Canada. , "Bacteria are drivers of nutrient ... said. "As the climate is changing, so are ...
(Date:9/16/2014)... Three years after the Hesperides vessel returned to Spain ... researchers have an increasingly clear picture of how the ... Specifically, the input of pollutants from the atmosphere is ... the most remote areas of the planet, and it ... findings are presented this week in CSIC Residence for ...
Breaking Biology News(10 mins):Meteorite that doomed the dinosaurs helped the forests bloom 2Meteorite that doomed the dinosaurs helped the forests bloom 3New research decodes virus-host interactions in ocean dead zones 2New research decodes virus-host interactions in ocean dead zones 3The Malaspina Expedition confirms that pollution reaches even the most remote areas of the ocean 2The Malaspina Expedition confirms that pollution reaches even the most remote areas of the ocean 3
... , May 30, 2013  Chiltern International Limited (Chiltern), a global ... Barbee to the position of Vice President, Global Biometrics. ... Chiltern stated: "We are extremely pleased to announce the promotion of ... to VP of Global Biometrics. In this role, Alecia will have ...
... for final exams might want to wait before pulling ... as their neurons are concerned. Carnegie Mellon University neuroscientists ... during which repeated exposure to a stimulus shrinks synapses. ... of the Journal of Neuroscience . It,s ...
... summit in Lough Erne, Northern Ireland, the German National ... science academies of the G8 member states and five ... state and government of the eight leading industrialised nations ... immediate future: drug-resistant infectious agents and sustainable development. The ...
Cached Biology News:Chiltern Announces The Promotion Of Alecia Barbee To VP, Global Biometrics 2Carnegie Mellon neuroscientists discover new phase of synaptic development 2The German National Academy of Sciences Leopoldina makes recommendations for the G8 summit 2
... screening, low melting point agarose where separation ... recommended for separation of nucleic acids less ... products. Micro ABgarose is also suited to ... blotting techniques. At a 3% concentration, Micro ...
Rabbit polyclonal to P5 ( Abpromise for all tested applications). entrezGeneID: 10954 SwissProtID: Q14554...
... Abpromise for all tested applications). ... derived from within residues 1 - 100 of ... is proprietary) (Peptide available as ... ID: 5453 Swiss Protein ...
Goat polyclonal to Sarcosine Oxidase ( Abpromise for all tested applications). Antigen: Microbial Sarcosine Oxidase. Entrez Gene ID: 51268 Swiss Protein ID: Q6IAJ9...
Biology Products: